Age at Onset and Presenting Symptoms of Neurofibromatosis Type 2 as Prognostic Factors for Clinical Course of Vestibular Schwannomas.
growth rate
hearing preservation
neurofibromatosis type 2
presenting symptom
vestibular schwannoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Aug 2020
20 Aug 2020
Historique:
received:
14
06
2020
revised:
17
08
2020
accepted:
18
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
The presenting symptoms of the tumor suppressor gene syndrome neurofibromatosis type 2 (NF2) are often non-specific and unrelated to the disease hallmark bilateral vestibular schwannomas (VS). However, age at onset and presenting symptoms may have predictive values for the clinical course of VS. In this retrospective single-center study, we addressed this issue by reviewing 106 patients with 194 VS. Presenting symptoms attributable to VS commonly occur in 87% of adults and 31% of children. Age at onset significantly correlates with tumor volumes at presentation (
Identifiants
pubmed: 32825434
pii: cancers12092355
doi: 10.3390/cancers12092355
pmc: PMC7563356
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medical Faculty Tübingen
ID : 2565-0-0
Références
Front Neurol. 2018 Sep 10;9:733
pubmed: 30250447
PLoS One. 2012;7(9):e46132
pubmed: 23049959
World J Clin Cases. 2014 Nov 16;2(11):608-13
pubmed: 25405184
J Clin Oncol. 2019 Dec 10;37(35):3446-3454
pubmed: 31626572
J Neurosurg Pediatr. 2014 Jun;13(6):650-7
pubmed: 24724714
Neurology. 2002 Dec 10;59(11):1759-65
pubmed: 12473765
Am J Med Genet A. 2012 Jan;158A(1):24-41
pubmed: 22140088
Neuropediatrics. 2005 Feb;36(1):21-34
pubmed: 15776319
Eye (Lond). 2016 Sep;30(9):1160-9
pubmed: 27518543
Arch Dis Child. 1999 Dec;81(6):496-9
pubmed: 10569966
Neurooncol Pract. 2016 Dec;3(4):281-289
pubmed: 29692918
Am J Med Genet. 1994 Oct 1;52(4):450-61
pubmed: 7747758
Adv Exp Med Biol. 2010;686:77-86
pubmed: 20824440
Otol Neurotol. 2012 Aug;33(6):1046-52
pubmed: 22805104
Genet Med. 2011 Jun;13(6):576-81
pubmed: 21451418
Arch Dis Child. 2018 May;103(5):463-469
pubmed: 29535107
Clin Cancer Res. 2017 Jun 15;23(12):e54-e61
pubmed: 28620005
Retina. 2010 Apr;30(4 Suppl):S51-8
pubmed: 20386093
J Neurosurg. 2003 Sep;99(3):480-3
pubmed: 12959433
Nat Clin Pract Oncol. 2008 Aug;5(8):487-91
pubmed: 18560388
Curr Neuropharmacol. 2010 Jun;8(2):128-34
pubmed: 21119884
Childs Nerv Syst. 2020 Oct;36(10):2463-2470
pubmed: 32537663
Arch Dermatol. 1997 Dec;133(12):1539-43
pubmed: 9420538
Lancet. 2009 Jun 6;373(9679):1974-86
pubmed: 19476995
Nature. 1993 Jun 10;363(6429):515-21
pubmed: 8379998
J Neurosurg Pediatr. 2019 Aug 23;:1-9
pubmed: 31443078
Am J Hum Genet. 2002 Oct;71(4):715-23
pubmed: 12235555
Cell. 1993 Nov 19;75(4):826
pubmed: 8242753
J Child Neurol. 2003 Oct;18(10):718-24
pubmed: 14649556
Cancers (Basel). 2019 Nov 25;11(12):
pubmed: 31769423
PLoS One. 2018 Feb 14;13(2):e0191857
pubmed: 29444106
N Engl J Med. 2009 Jul 23;361(4):358-67
pubmed: 19587327
Brain Dev. 2014 Feb;36(2):148-52
pubmed: 23414620
J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003
pubmed: 11589430
Neurosurgery. 1997 Feb;40(2):248-60; discussion 260-2
pubmed: 9007856
Cancers (Basel). 2019 Oct 07;11(10):
pubmed: 31591325
Semin Pediatr Neurol. 1998 Dec;5(4):243-52
pubmed: 9874852
Sci Rep. 2015 Dec 22;5:18599
pubmed: 26690506
Neurosurgery. 1993 Jul;33(1):92-6
pubmed: 8355853
Neurology. 2019 Sep 3;93(10):e964-e967
pubmed: 31363058
Neurogenetics. 2013 May;14(2):89-98
pubmed: 23377185
Cancers (Basel). 2019 Sep 16;11(9):
pubmed: 31527541
Biomed Rep. 2016 Dec;5(6):681-685
pubmed: 28101341
Q J Med. 1992 Aug;84(304):603-18
pubmed: 1484939
JAMA Neurol. 2017 Sep 1;74(9):1123-1129
pubmed: 28759666
J Med Genet. 1998 Jun;35(6):450-5
pubmed: 9643284
Klin Monbl Augenheilkd. 1996 Jan;208(1):58-62
pubmed: 8839347